ALCLS Cellectis SA

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)

PARIS, 04 févr. 2025 (GLOBE NEWSWIRE) --

Place de cotation : Euronext Growth

ISIN code: FR0010425595

   
DateNombre total d’actions composant le capital socialNombre total de droits de vote
31/01/2025100 093 87388 660 571
   

Pour de plus amples informations sur Cellectis, veuillez contacter :        

Contact média :        

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Contacts pour les relations avec les investisseurs :        

Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980,

Pièce jointe



EN
04/02/2025

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

Christophe-Raphaël Ganet ... (+2)
  • Christophe-Raphaël Ganet
  • Stephane Beyazian
FRA FRAPORT AG
SZG SALZGITTER AG
MRN MERSEN SA
ALCLS CELLECTIS SA
SDF K+S AG
MIL BANK MILLENNIUM SA
SIX2 SIXT SE
COK CANCOM SE
VASTB VASTNED RETAIL BELGIUM NV
KENDR KENDRION NV
TWEKA TKH GROUP N.V. CERT
ALM ALMIRALL SA
DUE DURR AG
BSGR B&S GROUP S.A.
ALFEN ALFEN NV
JEN JENOPTIK AG
HGEA HGEARS AG
IOS IONOS GROUP SE
SPG SPRINGER NATURE AG & CO. KGAA
05/13/25 May 13, 2025 1 EN
Christophe-Raphaël Ganet ... (+2)
  • Christophe-Raphaël Ganet
  • Stephane Beyazian
FRA FRAPORT AG
SZG SALZGITTER AG
MRN MERSEN SA
ALCLS CELLECTIS SA
SDF K+S AG
MIL BANK MILLENNIUM SA
SIX2 SIXT SE
COK CANCOM SE
VASTB VASTNED RETAIL BELGIUM NV
KENDR KENDRION NV
TWEKA TKH GROUP N.V. CERT
ALM ALMIRALL SA
DUE DURR AG
BSGR B&S GROUP S.A.
ALFEN ALFEN NV
JEN JENOPTIK AG
HGEA HGEARS AG
IOS IONOS GROUP SE
SPG SPRINGER NATURE AG & CO. KGAA
05/13/25 May 13, 2025 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
05/13/25 May 13, 2025 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
05/13/25 May 13, 2025 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Reports Financial Results for the First Quarter 2025

Cellectis Reports Financial Results for the First Quarter 2025 Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderCellectis will present novel non-viral gene editing and base editing rese...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch